A 228839

Drug Profile

A 228839

Alternative Names: A-228839; ABT 839

Latest Information Update: 24 Jan 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Class
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Transplant rejection

Most Recent Events

  • 18 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 18 Sep 2006 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
  • 23 Jun 2003 Data presented at the 4th Annual Meeting of the American Transplant Congress (ATC-2003) have been added to the Transplant Rejection therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top